Posted by Michael Wonder on 13 May 2021
Eisai Korea to stop supply of blood cancer drug Symbenda this year
13 May 2021 - Symbenda (bendamustine), a treatment for blood cancer, is expected to become unavailable in Korea within this year, but generic drugs are expected to replace the original medicine, industry officials said.
Eisai Korea reportedly notified the Ministry of Food and Drug Safety in April that it would discontinue the supply of Symbenda in the local market.
Symbenda won the regulatory nod for follicular lymphoma, chronic lymphocytic leukaemia, and multiple myeloma in 2011 and became reimbursable in September 2018.
